BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24074814)

  • 1. Severe late esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy.
    Chen C; Uyterlinde W; Sonke JJ; de Bois J; van den Heuvel M; Belderbos J
    Radiother Oncol; 2013 Aug; 108(2):337-41. PubMed ID: 24074814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
    Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
    Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute esophagus toxicity in lung cancer patients after intensity modulated radiation therapy and concurrent chemotherapy.
    Kwint M; Uyterlinde W; Nijkamp J; Chen C; de Bois J; Sonke JJ; van den Heuvel M; Knegjens J; van Herk M; Belderbos J
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):e223-8. PubMed ID: 22560551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment-related acute esophagitis for patients with locoregionally advanced non-small cell lung cancer treated with involved-field radiotherapy and concurrent chemotherapy.
    Bar-Ad V; Leiby B; Witek M; Xiao Y; Cui Y; Dai Y; Cao J; Axelrod R; Campling B; Both S; Werner-Wasik M
    Am J Clin Oncol; 2014 Oct; 37(5):433-7. PubMed ID: 23388558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic parameters for acute esophagus toxicity in intensity modulated radiotherapy and concurrent chemotherapy for locally advanced non-small cell lung cancer.
    Uyterlinde W; Chen C; Kwint M; de Bois J; Vincent A; Sonke JJ; Belderbos J; van den Heuvel M
    Radiother Oncol; 2013 Jun; 107(3):392-7. PubMed ID: 23647749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Contralateral Esophagus-Sparing Technique to Limit Severe Esophagitis Associated With Concurrent High-Dose Radiation and Chemotherapy in Patients With Thoracic Malignancies.
    Al-Halabi H; Paetzold P; Sharp GC; Olsen C; Willers H
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):803-10. PubMed ID: 26104934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy.
    Kim TH; Cho KH; Pyo HR; Lee JS; Han JY; Zo JI; Lee JM; Hong EK; Choi IJ; Park SY; Shin KH; Kim DY; Kim JY
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):995-1002. PubMed ID: 15990000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small-cell lung cancer.
    Sekine I; Sumi M; Ito Y; Horinouchi H; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Kubota K; Tamura T
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):953-9. PubMed ID: 21377282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multivariable normal-tissue complication modeling of acute esophageal toxicity in advanced stage non-small cell lung cancer patients treated with intensity-modulated (chemo-)radiotherapy.
    Wijsman R; Dankers F; Troost EG; Hoffmann AL; van der Heijden EH; de Geus-Oei LF; Bussink J
    Radiother Oncol; 2015 Oct; 117(1):49-54. PubMed ID: 26341608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94).
    Ghadjar P; Simcock M; Zimmermann F; Betz M; Bodis S; Bernier J; Studer G; Aebersold DM;
    Radiother Oncol; 2012 Aug; 104(2):213-8. PubMed ID: 22726581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An esophagus-sparing technique to limit radiation esophagitis in locally advanced non-small cell lung cancer treated by simultaneous integrated boost intensity-modulated radiotherapy and concurrent chemotherapy.
    Ma L; Qiu B; Li Q; Chen L; Wang B; Hu Y; Liu M; Zhang L; Huang Y; Deng X; Xia Y; Lin M; Liu H
    Radiat Oncol; 2018 Jul; 13(1):130. PubMed ID: 30016978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy.
    Belderbos J; Heemsbergen W; Hoogeman M; Pengel K; Rossi M; Lebesque J
    Radiother Oncol; 2005 May; 75(2):157-64. PubMed ID: 15890421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normal tissue complication probability analysis of acute gastrointestinal toxicity in cervical cancer patients undergoing intensity modulated radiation therapy and concurrent cisplatin.
    Simpson DR; Song WY; Moiseenko V; Rose BS; Yashar CM; Mundt AJ; Mell LK
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e81-6. PubMed ID: 22516388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer.
    Chapet O; Kong FM; Lee JS; Hayman JA; Ten Haken RK
    Radiother Oncol; 2005 Nov; 77(2):176-81. PubMed ID: 16256230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience.
    Jiang ZQ; Yang K; Komaki R; Wei X; Tucker SL; Zhuang Y; Martel MK; Vedam S; Balter P; Zhu G; Gomez D; Lu C; Mohan R; Cox JD; Liao Z
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):332-9. PubMed ID: 22079735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis.
    Rodrigues G; Oberije C; Senan S; Tsujino K; Wiersma T; Moreno-Jimenez M; Kim TH; Marks LB; Rengan R; De Petris L; Ramella S; DeRuyck K; De Dios NR; Warner A; Bradley JD; Palma DA
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):133-9. PubMed ID: 25835622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity and outcome results of a class solution with moderately hypofractionated radiotherapy in inoperable Stage III non-small cell lung cancer using helical tomotherapy.
    Bral S; Duchateau M; Versmessen H; Engels B; Tournel K; Vinh-Hung V; De Ridder M; Schallier D; Storme G
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1352-9. PubMed ID: 20056350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
    Yom SS; Liao Z; Liu HH; Tucker SL; Hu CS; Wei X; Wang X; Wang S; Mohan R; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):94-102. PubMed ID: 17321067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: analysis of the radiation therapy oncology group (RTOG) database.
    Werner-Wasik M; Paulus R; Curran WJ; Byhardt R
    Clin Lung Cancer; 2011 Jul; 12(4):245-51. PubMed ID: 21726824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External validation of an NTCP model for acute esophageal toxicity in locally advanced NSCLC patients treated with intensity-modulated (chemo-)radiotherapy.
    Dankers FJWM; Wijsman R; Troost EGC; Tissing-Tan CJA; Kwint MH; Belderbos J; de Ruysscher D; Hendriks LE; de Geus-Oei LF; Rodwell L; Dekker A; Monshouwer R; Hoffmann AL; Bussink J
    Radiother Oncol; 2018 Nov; 129(2):249-256. PubMed ID: 30241789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.